Antibiotics have long been effective medications for treating bacterial infections. However, some bacteria have begun to exhibit "antibiotic resistance," rendering them resistant to multiple antibiotics, and they are often referred to as "superbugs." Recently, Prof. Chen Sheng and his team have discovered two novel treatment approaches for the treatment of infections caused by antibiotic-resistant superbugs. These approaches have demonstrated excellent efficacy and significant potential for clinical application. The research findings have been published in two prestigious journals: Signal Transduction and Targeted Therapy and the Journal of Infection.
Prof. Chen and his team identified a new variant of Klebsiella pneumoniae, known as hyper-resistant and hypervirulent Klebsiella pneumoniae (CR-hvKP). Remarkably, within just five years after the discovery of the CR-hvKP strain, they have simultaneously identified two promising treatment options that can be used individually or in combination to neutralize the threat posed by this highly drug-resistant and virulent pathogen. Timely treatment not only reduces mortality but also curbs the spread of the pathogen. The team is planning to conduct clinical trials to validate their findings, with the ultimate goal of significantly reducing the mortality rate associated with CR-hvKP infections.